Drug Profile
Research programme: Pim kinase inhibitors - Array BioPharma
Alternative Names: AR 29; ARRY-Pim-iLatest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class Small molecules
- Mechanism of Action Protein-serine-threonine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Myeloid leukaemia
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 12 Aug 2011 No development reported - Preclinical for Myeloid leukaemia in USA (PO)
- 08 Dec 2009 Pharmacodynamics data from preclinical trials in Myeloid leukaemia presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)